300294.SZ
博雅生物
SZSE · Healthcare · C 制造业 · CN
CNY 14.43
−4.94%Year over year
Reported trailing growth
- Revenue
- +1.2%
- EBITDA
- —
- EBIT
- —
- EPS
- -98.0%
- Free cash flow
- —
- Operating cash flow
- —
Forward estimates
Based on analyst estimates
- Revenue
- -65.6%
- EBITDA
- -75.9%
- EPS
- +4450.4%
Three-year CAGR
- Revenue
- -9.3%
- EBITDA
- -25.1%
- EBIT
- -41.0%
- Net income
- -36.1%
- EPS
- -36.5%
- Free cash flow
- —
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026